Pharmac backtracks on plan to fund lung cancer drug Keytruda

Brian from New Lynn

The move has dashed hopes that Keytruda would soon be publicly funded for lung cancer - New Zealand's biggest cancer killer. RNZ has obtained documents showing Pharmac had planned to offer a Request for Proposals, or RFP, where drug companies are asked to pitch their products and prices, but has put that on hold due to budget constraints. Chief executive Sarah Fitt told RNZ that Pharmac was concerned about rising drug prices worldwide in the Covid-19 pandemic and that it could not commit to funding the drug now - but still hoped to in the future.
Lung cancer patients and their advocates are devastated and said they had been given false hope. Keytruda is available in New Zealand but patients must fund it themselves. "So what we now have is 30 lung cancer patients continuing to die prematurely every week and you have to ask yourself, is that acceptable?" Fitt said funding a drug like Keytruda for lung cancer would have cost hundreds of millions over the next five years and Pharmac could not commit to that given the Covid-19 outbreak.
========================================================